GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Discussion] can we stop arguing about endpoint until somebody posts a number — 36 comments in the full submission. View in context.
1.1k
c/trialwatch·submitted 1 year ago by u/nikhil_lindqvist

[Discussion] can we stop arguing about endpoint until somebody posts a number

Discussionbranch of 5 comments

Right, the SURMOUNT question again, but with numbers this time. I have 21 data points over 14 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am…

Read the full submission and all 36 comments →

This branch

5 comments, started 1 year ago
u/ahmed_iyer68 points·1 year ago

off-label use data is different from approved-indication data

replysharereportpermalink
u/zaid_roos19 points·1 year ago

off-label use data is different from approved-indication data

Yes, exactly this, and it is the bit that took me 81 weeks to accept.

replysharereportpermalink
u/nikhil_lindqvistOP14 points·1 year ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/nightowl_injector4 points·1 year ago

give the trial name, phase, n, and primary endpoint in the body

replysharereportpermalink
u/anders_kuusela-26 points·1 year ago

the discontinuation arms are the interesting part, not the FLOW endpoints

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →